ICRP Publication 94: Release of Patients after Therapy with Unsealed Radionuclides

Author:   ICRP
Publisher:   Elsevier Health Sciences
Edition:   Gorgias Press and Us and Updated to Include New Develop and
Volume:   v. 94
ISBN:  

9780080445601


Pages:   84
Publication Date:   25 May 2005
Format:   Paperback
Availability:   Out of stock   Availability explained
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Our Price $166.95 Quantity:  
Add to Cart

Share |

ICRP Publication 94: Release of Patients after Therapy with Unsealed Radionuclides


Add your own review!

Overview

After some therapeutic nuclear medicine procedures with unsealed radionuclides, precautions may be needed to limit doses to other people, but this is rarely the case after diagnostic procedures. Iodine-131 results in the largest dose to medical staff, the public, caregivers, and relatives. Other radionuclides used in therapy are usually simple beta emitters (e.g. phosphorus-32, strontium-89, and yttrium-90) that pose much less risk. Dose limits apply to exposure of the public and medical staff from patients. Previously, the ICRP has recommended that a source-related dose constraint for optimisation of a few mSv/episode applies to relatives, visitors, and caregivers at home, rather than a dose limit. The present report recommends that young children and infants, as well as visitors not engaged in direct care or comforting, should be treated as members of the public (i.e. be subject to the public dose limit). The modes of exposure to other people are: external exposure; internal exposure due to contamination; and environmental pathways. Dose to adults from patients is mainly due to external exposure. Contamination of infants and children with saliva from a patient could result in significant doses to the child's thyroid. It is important to avoid contamination of children and pregnant women. After radioiodine therapy, mothers must cease breastfeeding immediately. Many types of therapy with unsealed radionuclides are contraindicated in pregnant females. Women should not become pregnant for some time after radioisotope therapy. Technetium-99m dominates discharges to the environment from excreta of nuclear medicine patients, but its short half-life limits its importance. The second largest discharges, iodine-131, can be detected in the environment after medical uses but with no measurable environmental impact. Storing patients' urine after therapy appears to have minimal benefit.

Full Product Details

Author:   ICRP
Publisher:   Elsevier Health Sciences
Imprint:   Elsevier Health Sciences
Edition:   Gorgias Press and Us and Updated to Include New Develop and
Volume:   v. 94
Dimensions:   Width: 17.00cm , Height: 0.50cm , Length: 24.40cm
Weight:   0.170kg
ISBN:  

9780080445601


ISBN 10:   0080445608
Pages:   84
Publication Date:   25 May 2005
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Out of stock   Availability explained
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

Aorrng

Shopping Cart
Your cart is empty
Shopping cart
Mailing List